Results 21 to 30 of about 17,704 (165)

Kinase profiling of liposarcomas using RNAi and drug screening assays identified druggable targets

open access: yesJournal of Hematology & Oncology, 2017
Background Liposarcoma, the most common soft tissue tumor, is understudied cancer, and limited progress has been made in the treatment of metastatic disease.
Deepika Kanojia   +9 more
doaj   +1 more source

Characteristics of Liposarcoma Patients: 5-Year Data

open access: yesAlthea Medical Journal, 2018
Background: Liposarcoma is the second highest soft tissue sarcoma in adults with prevalence of 15% to 25%. If the size of liposarcoma is very large, it may cause abdominal pain, weight loss, gastrointestinal bleeding, even kidney failure.
Miftahur Rahmah   +2 more
doaj   +1 more source

Solitary metastasis of myxoid liposarcoma from the thigh to intraperitoneum: a case report

open access: yesWorld Journal of Surgical Oncology, 2019
Background The purpose of case report was to present a rare case of a solitary metastasis of myxoid liposarcoma and discuss the clinical and pathological information for patients treated for metastatic myxoid liposarcoma.
Dong-Wook Kim, Ye Seob Jee
doaj   +1 more source

A Giant Retroperitoneal Liposarcoma Encasing the Entire Left Kidney and Adherent to Adjacent Structures: A Case Report

open access: yesCase Reports in Oncology, 2016
Retroperitoneal liposarcoma is a rare tumor. The dimension and weight of liposarcoma are variable; those over 20 kg are called ‘giant liposarcoma’.
Sung Don  Oh   +7 more
doaj   +1 more source

Deep Learning‐Assisted Coherent Raman Scattering Microscopy

open access: yesAdvanced Intelligent Discovery, EarlyView.
The analytical capabilities of coherent Raman scattering microscopy are augmented through deep learning integration. This synergistic paradigm improves fundamental performance via denoising, deconvolution, and hyperspectral unmixing. Concurrently, it enhances downstream image analysis including subcellular localization, virtual staining, and clinical ...
Jianlin Liu   +4 more
wiley   +1 more source

Giant paratesticular liposarcoma with lung metastases: a case report and review of the literature

open access: yesJournal of Medical Case Reports, 2020
Background Due to its rarity, little is known about the clinical presentations and responses to systemic chemotherapies in advanced and/or metastatic cases of paratesticular liposarcoma.
Takuro Noguchi   +7 more
doaj   +1 more source

Skull Base Surgery in the Pediatric Population—The 2nd International Collaborative Study (1995–2015)

open access: yesHead &Neck, EarlyView.
ABSTRACT Background The current study presents the efforts of a global collaborative group to review the management and outcomes of malignant tumors of the skull base in the pediatric population worldwide. Patients and Methods A total of 28 institutions contributed data on 3061 patients. From this, there were 64 pediatric patients (2.1%).
Dan M. Fliss   +50 more
wiley   +1 more source

Comprehensive genomic profiling of a unique liposarcoma arising in a patient with Li–Fraumeni syndrome and the novel detection of c-myc amplification: a case report

open access: yesDiagnostic Pathology, 2022
Background Germline TP53 mutations have been frequently reported in patients with Li–Fraumeni syndrome (LFS), resulting in a predisposition to various malignancies.
Hirofumi Watanabe   +10 more
doaj   +1 more source

Retroperitoneal Liposarcoma

open access: yesAnnals of Surgery, 1978
A group of patients with retroperitoneal liposarcoma is presented and general guidelines of management reviewed. It is suggested that aggressive, radical total surgical excision followed by adjuvant postoperative irradiation be used as the treatment of choice.
S C, Binder, B, Katz, B, Sheridan
openaire   +3 more sources

Clinical trial of safety and antitumor activity of farletuzumab ecteribulin in patients with platinum‐resistant ovarian cancer: Phase I expansion results

open access: yesInternational Journal of Gynecology &Obstetrics, EarlyView.
Abstract Objective In the dose‐escalation part of Study 101, which included multiple tumor types, objective responses were observed in 10 of 22 patients across multiple dose levels of farletuzumab ecteribulin (FZEC). We explored the safety/antitumor activity of FZEC in patients with platinum‐resistant ovarian cancer (PROC) from the Study 101 expansion ...
Kan Yonemori   +11 more
wiley   +1 more source

Home - About - Disclaimer - Privacy